[{"address1": "3891 Ranchero Drive", "address2": "Suite 150", "city": "Ann Arbor", "state": "MI", "zip": "48108", "country": "United States", "phone": "734 887 3903", "website": "https://www.esperion.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.", "fullTimeEmployees": 304, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sheldon L. Koenig", "age": 58, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 1262378, "exercisedValue": 0, "unexercisedValue": 18056}, {"maxAge": 1, "name": "Mr. Benjamin  Halladay M.B.A.", "age": 38, "title": "Chief Financial Officer", "yearBorn": 1986, "fiscalYear": 2024, "totalPay": 713958, "exercisedValue": 0, "unexercisedValue": 5625}, {"maxAge": 1, "name": "Mr. Benjamin O. Looker J.D.", "age": 42, "title": "General Counsel & Corporate Secretary", "yearBorn": 1982, "fiscalYear": 2024, "totalPay": 696350, "exercisedValue": 0, "unexercisedValue": 4219}, {"maxAge": 1, "name": "Tiffany  Aldrich M.B.A.", "title": "Associate Director of Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Betty Jean Swartz", "title": "Chief Business Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Glenn P. Brame", "age": 66, "title": "Chief Technical Operations Officer", "yearBorn": 1958, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stephen  Pinkosky", "title": "Vice President of Drug Discovery of Early Pre-Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.15, "open": 1.15, "dayLow": 1.15, "dayHigh": 1.215, "regularMarketPreviousClose": 1.15, "regularMarketOpen": 1.15, "regularMarketDayLow": 1.15, "regularMarketDayHigh": 1.215, "payoutRatio": 0.0, "beta": 0.654, "forwardPE": 5.85, "volume": 2321688, "regularMarketVolume": 2321688, "averageVolume": 5116814, "averageVolume10days": 3067300, "averageDailyVolume10Day": 3067300, "bid": 0.8568, "ask": 1.48, "bidSize": 2, "askSize": 2, "marketCap": 231892832, "fiftyTwoWeekLow": 0.69, "fiftyTwoWeekHigh": 3.94, "priceToSalesTrailing12Months": 0.89335924, "fiftyDayAverage": 0.9816, "twoHundredDayAverage": 1.71905, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 674477568, "profitMargins": -0.59028, "floatShares": 196037106, "sharesOutstanding": 198199008, "sharesShort": 24113664, "sharesShortPriorMonth": 27945316, "sharesShortPreviousMonthDate": 1747267200, "dateShortInterest": 1749772800, "sharesPercentSharesOut": 0.121700004, "heldPercentInsiders": 0.00575, "heldPercentInstitutions": 0.59273, "shortRatio": 4.98, "shortPercentOfFloat": 0.122200005, "impliedSharesOutstanding": 198199008, "bookValue": -2.167, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -153222000, "trailingEps": -0.85, "forwardEps": 0.2, "enterpriseToRevenue": 2.598, "enterpriseToEbitda": -16.898, "52WeekChange": -0.5125, "SandP52WeekChange": 0.12677538, "quoteType": "EQUITY", "currentPrice": 1.17, "targetHighPrice": 16.0, "targetLowPrice": 1.5, "targetMeanPrice": 5.78571, "targetMedianPrice": 4.0, "recommendationMean": 2.28571, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 114633000, "totalCashPerShare": 0.578, "ebitda": -39915000, "totalDebt": 594003008, "quickRatio": 0.723, "currentRatio": 1.176, "totalRevenue": 259574000, "revenuePerShare": 1.339, "returnOnAssets": -0.07166, "grossProfits": 124118000, "freeCashflow": -80851128, "operatingCashflow": -100110000, "revenueGrowth": -0.528, "grossMargins": 0.47816002, "ebitdaMargins": -0.15377, "operatingMargins": -0.33995998, "financialCurrency": "USD", "symbol": "ESPR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Esperion Therapeutics, Inc.", "longName": "Esperion Therapeutics, Inc.", "corporateActions": [], "postMarketTime": 1751575636, "regularMarketTime": 1751562001, "exchange": "NGM", "messageBoardId": "finmb_28236", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "fiftyDayAverageChange": 0.18839997, "fiftyDayAverageChangePercent": 0.19193152, "twoHundredDayAverageChange": -0.5490501, "twoHundredDayAverageChangePercent": -0.31939158, "priceToBook": -0.5399169, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.3 - Buy", "cryptoTradeable": false, "regularMarketChangePercent": 1.73913, "regularMarketPrice": 1.17, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1372253400000, "postMarketChangePercent": 0.8547001, "postMarketPrice": 1.18, "postMarketChange": 0.00999999, "regularMarketChange": 0.02, "regularMarketDayRange": "1.15 - 1.215", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 5116814, "fiftyTwoWeekLowChange": 0.47999996, "fiftyTwoWeekLowChangePercent": 0.6956521, "fiftyTwoWeekRange": "0.69 - 3.94", "fiftyTwoWeekHighChange": -2.77, "fiftyTwoWeekHighChangePercent": -0.70304567, "fiftyTwoWeekChangePercent": -51.25, "earningsTimestamp": 1746525600, "earningsTimestampStart": 1754915400, "earningsTimestampEnd": 1754915400, "earningsCallTimestampStart": 1746532800, "earningsCallTimestampEnd": 1746532800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.85, "epsForward": 0.2, "epsCurrentYear": -0.338, "priceEpsCurrentYear": -3.4615383, "marketState": "CLOSED", "displayName": "Esperion Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-07-05"}]